Zosano Pharma Corp. (fka ZSANQ)

[ash111]

a few taking profits today but be aware ZSAN Completed Enrollment in Pivotal Efficacy Trial for M207 for Acute Migraine early November and Financing was done around the 1.20-1.30 area
($19m Cash on hand).
on their Presentation mentioned a possible near term partnership for both osteoporosis & hypoglycemia- P2 Completed on both. this could take place even before Phase 3 on Q1 2017 imo.so beside upcoming P3,we have more possible Catalysts/Events.

$13m cap insane cheap for P2/P3 Co. on good data this could easily see the 180-200m market cap imo.

A strong Ownership too leaves the float only 4m:

41% ownership : http://www.nasdaq.com/symbol/zsan/ownership-summary a/o 30/9/2016 per NASDAQ.

Recent stakes:

1. by Rosalind Advisors, Inc 11.2% of Zosano Pharma Corp. (NASDAQ:ZSAN) in a Schedule 13G disclosure that was filed with the SEC on Wednesday, November 16th. owns 2,023,777 shares

2. Lombard Odier Asset Management USA Corp boosted its stake in Zosano Pharma Corp. by 66.7% in the third quarter. Lombard Odier Asset Management USA Corp now owns 795,722 shares

As of November 3, 2016, the registrant had a total of 16,815,997 shares of its common stock, $0.0001 par value per share, outstanding.

41% of 16.8m O/S= 6.8m - 2,023,777 - 795,722 = about 4m float